Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer : An Austrian Multicenter Study
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved..
INTRODUCTION: Two randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel), thus changing treatment strategies in metastatic hormonesensitive prostate cancer (mHSPC).
PATIENTS AND METHODS: We conducted the first real-world analysis comprising 97 mHSPC patients from 16 Austrian medical centers, among them 79.4% of patients received abiraterone and 17.5% darolutamide treatment. Baseline characteristics and clinical parameters during triplet therapy were documented. Mann-Whitney U test for continuous or X²-test for categorical variables was used. Variables on progression were tested using logistic regression analysis and tabulated as hazard ratios (HR), 95% confidence interval (CI).
RESULTS: Of 83.5% patients with synchronous and 16.5% with metachronous disease were included. 83.5% had high-volume disease diagnosed by conventional imaging (48.9%) or PSMA PET-CT (51.1%). While docetaxel and ARPI were administered consistent with pivotal trials, prednisolone, prophylactic gCSF and osteoprotective agents were not applied guideline conform in 32.5%, 37%, and 24.3% of patients, respectively. Importantly, a nonsimultaneous onset of chemotherapy and ARPI, performed in 44.3% of patients, was associated with significantly worse treatment response (P = .015, HR 0.245). Starting ARPI before chemotherapy was associated with significantly higher probability for progression (P = .023, HR 15.781) than vice versa. Strikingly, 15.6% (abiraterone) and 25.5% (darolutamide) low-volume patients as well as 14.4% (abiraterone) and 17.6% (darolutamide) metachronous patients received triplet therapy. Adverse events (AE) occurred in 61.9% with grade 3 to 5 in 15% of patient without age-related differences. All patients achieved a PSA decline of 99% and imaging response was confirmed in 88% of abiraterone and 75% of darolutamide patients.
CONCLUSIONS: Triplet therapy arrived in clinical practice primarily for synchronous high-volume mHSPC. Regardless of selected therapy regimen, treatment is highly effective and tolerable. Preferably therapy should be administered simultaneously, however if not possible, chemotherapy should be started first.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical genitourinary cancer - 22(2024), 2 vom: 24. Apr., Seite 458-466.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kafka, Mona [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
15H5577CQD |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clgc.2023.12.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367577321 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367577321 | ||
| 003 | DE-627 | ||
| 005 | 20240410232431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2023.12.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM367577321 | ||
| 035 | |a (NLM)38267304 | ||
| 035 | |a (PII)S1558-7673(24)00002-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kafka, Mona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer |b An Austrian Multicenter Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: Two randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel), thus changing treatment strategies in metastatic hormonesensitive prostate cancer (mHSPC) | ||
| 520 | |a PATIENTS AND METHODS: We conducted the first real-world analysis comprising 97 mHSPC patients from 16 Austrian medical centers, among them 79.4% of patients received abiraterone and 17.5% darolutamide treatment. Baseline characteristics and clinical parameters during triplet therapy were documented. Mann-Whitney U test for continuous or X²-test for categorical variables was used. Variables on progression were tested using logistic regression analysis and tabulated as hazard ratios (HR), 95% confidence interval (CI) | ||
| 520 | |a RESULTS: Of 83.5% patients with synchronous and 16.5% with metachronous disease were included. 83.5% had high-volume disease diagnosed by conventional imaging (48.9%) or PSMA PET-CT (51.1%). While docetaxel and ARPI were administered consistent with pivotal trials, prednisolone, prophylactic gCSF and osteoprotective agents were not applied guideline conform in 32.5%, 37%, and 24.3% of patients, respectively. Importantly, a nonsimultaneous onset of chemotherapy and ARPI, performed in 44.3% of patients, was associated with significantly worse treatment response (P = .015, HR 0.245). Starting ARPI before chemotherapy was associated with significantly higher probability for progression (P = .023, HR 15.781) than vice versa. Strikingly, 15.6% (abiraterone) and 25.5% (darolutamide) low-volume patients as well as 14.4% (abiraterone) and 17.6% (darolutamide) metachronous patients received triplet therapy. Adverse events (AE) occurred in 61.9% with grade 3 to 5 in 15% of patient without age-related differences. All patients achieved a PSA decline of 99% and imaging response was confirmed in 88% of abiraterone and 75% of darolutamide patients | ||
| 520 | |a CONCLUSIONS: Triplet therapy arrived in clinical practice primarily for synchronous high-volume mHSPC. Regardless of selected therapy regimen, treatment is highly effective and tolerable. Preferably therapy should be administered simultaneously, however if not possible, chemotherapy should be started first | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abiraterone | |
| 650 | 4 | |a Darolutamide | |
| 650 | 4 | |a Personalized treatment | |
| 650 | 4 | |a Treatment efficacy | |
| 650 | 4 | |a Triplet therapy tolerability | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a Hormones |2 NLM | |
| 700 | 1 | |a Giannini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Artamonova, Nastasiia |e verfasserin |4 aut | |
| 700 | 1 | |a Neuwirt, Hannes |e verfasserin |4 aut | |
| 700 | 1 | |a Ofner, Heidemarie |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, Gero |e verfasserin |4 aut | |
| 700 | 1 | |a Bauernhofer, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Luger, Ferdinand |e verfasserin |4 aut | |
| 700 | 1 | |a Höfner, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Loidl, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Griessner, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Lusuardi, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Bergmaier, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Winder, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Bauinger, Severin |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Drerup, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Heinrich, Elmar |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Madersbacher, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Vallet, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Stoiber, Franz |e verfasserin |4 aut | |
| 700 | 1 | |a Laimer, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Hruby, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Schachtner, Gert |e verfasserin |4 aut | |
| 700 | 1 | |a Nagele, Udo |e verfasserin |4 aut | |
| 700 | 1 | |a Lenart, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Ponholzer, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Pfuner, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Wiesinger, Clemens |e verfasserin |4 aut | |
| 700 | 1 | |a Kamhuber, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Müldür, Ecan |e verfasserin |4 aut | |
| 700 | 1 | |a Bektic, Jasmin |e verfasserin |4 aut | |
| 700 | 1 | |a Horninger, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Heidegger, Isabel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d 2005 |g 22(2024), 2 vom: 24. Apr., Seite 458-466.e1 |w (DE-627)NLM160229936 |x 1938-0682 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:2 |g day:24 |g month:04 |g pages:458-466.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clgc.2023.12.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 2 |b 24 |c 04 |h 458-466.e1 | ||